90 completed, 33 terminated, 7 active not recruiting, 7 unknown. 95 Phase 2, 36 Phase 1, 11 Phase 3, 3 Not applicable.
Follow Sunitinib Malate: new trials by email Literature Review of Sunitinib Malate trials Research Report on Sunitinib Malate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2024-08-14 | 2026-10-20 |
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Exelixis | 317 | 2023-01-01 | 2026-07-29 |
| Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 60 | 2019-10-01 | 2020-11-13 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion GB-102 - Diabetic Macular Edema, Retina Vein Occlusion | Phase 2 | Completed | Graybug Vision | 21 | 2019-09-11 | 2021-11-22 |
| Losartan + Sunitinib in Treatment of Osteosarcoma Losartan, Sunitinib - Osteosarcoma | Phase 1 | Recruiting | University of Colorado, Denver | 41 | 2019-08-26 | 2026-09-01 |
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Laboratory Biomarker Analysis, Pembrolizumab, Sunitinib Malate - Thymic Carcinoma | Phase 2 | Active not recruiting | Dwight Owen | 9 | 2018-06-19 | 2026-08-06 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2018-05-15 | 2026-07-16 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population Sunitinib malate - Renal Cell Carcinoma | Phase 2 | Terminated | vghtpe user | 13 | 2015-08-12 | 2018-06-26 |
| Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma Sunitinib, Valproic Acid, Sunitinib Malate - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 210 | 2014-11-19 | 2026-10-22 |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) Sunitinib, Questionnaire - Genitourinary Cancer, Kidney Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 60 | 2014-08-01 | 2020-02-27 |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 157 | 2013-07-08 | 2021-02-11 |
| Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer transcranial magnetic stimulation, electromyography, survey administration - Fatigue, Recurrent Renal Cell Cancer | Not applicable | Terminated | Case Comprehensive Cancer Center | 13 | 2012-09-01 | 2018-12-06 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate - Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2012-08-01 | 2022-06-07 |
| A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor sunitinib malate dose escalation, sunitinib malate - Gastrointestinal Stromal Tumors | Phase 2 | Completed | Pfizer | 6 | 2012-06-01 | 2019-03-27 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Antitumor Drug Screening Assay, Dasatinib, Idelalisib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 12 | 2012-05-11 | 2021-11-04 |
Showing 20 of 142. Sign in to see all of them.
Carcinoma, Renal Cell (41) · Kidney Neoplasms (21) · Breast Neoplasms (9) · Neoplasm Metastasis (8) · Prostatic Neoplasms (7) · Urinary Bladder Neoplasms (7) · Carcinoma, Hepatocellular (6) · Esophageal Neoplasms (5) · Gastrointestinal Stromal Tumors (5) · Melanoma (5) · Pancreatic Neoplasms (5) · Uveal Melanoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Leukemia, Myeloid, Acute (4) · Leukemia, Myelomonocytic, Chronic (4)
National Cancer Institute (NCI) (34) · Pfizer (17) · M.D. Anderson Cancer Center (13) · Case Comprehensive Cancer Center (6) · Memorial Sloan Kettering Cancer Center (5) · Roswell Park Cancer Institute (4) · Graybug Vision (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · OHSU Knight Cancer Institute (3) · University of Washington (3) · Abramson Cancer Center at Penn Medicine (2) · Federation Francophone de Cancerologie Digestive (2) · US Oncology Research (2) · University of California, San Francisco (2) · AEterna Zentaris (1)
United States (105) · Canada (18) · France (13) · South Korea (11) · United Kingdom (11) · Australia (10) · Spain (10) · Italy (8) · Germany (7) · Taiwan (6) · Netherlands (5) · Argentina (4) · Czechia (4) · Hong Kong (4) · Poland (4)
Eric Jonasch, MD (3) · Robert J. Motzer, MD (3) · Amado Zurita, MD (2) · Brian Rini (2) · Dean F. Bajorin, MD (2) · Glenn Liu (2) · Hope S. Rugo, MD (2) · Jonathan Strosberg, MD (2) · Nizar M. Tannir, MD (2) · Alain Ravaud, MD, PhD (1) · Aminah Jatoi, MD (1) · Amit M Oza (1)
PMID 33852135, PMID 20203173, PMID 32623479, PMID 37146227, PMID 19451429, PMID 19536893, PMID 19547919, PMID 20711632, PMID 20818327, PMID 20975250, PMID 21148613, PMID 21174224, PMID 21306237, PMID 21898376, PMID 22105611, PMID 22259028, PMID 22261812, PMID 22425095, PMID 22614181, PMID 22761653, PMID 23228446, PMID 23660867, PMID 23676418, PMID 24081937, PMID 24091982, PMID 24158411, PMID 24268852, PMID 24308791, PMID 24474568, PMID 24821582, PMID 24882554, PMID 25085632, PMID 25532471, PMID 25577718, PMID 25732163, PMID 25802238, PMID 26151457, PMID 26582660, PMID 26586415, PMID 26969090, PMID 27029034, PMID 27109549, PMID 27217543, PMID 27238653, PMID 27718781, PMID 27836885, PMID 27924459, PMID 28161554, PMID 28278333, PMID 28410911
U10CA031946 (5), N01CM62201 (4), P30CA008748 (4), P30CA043703 (4), U10CA180821 (4), N01CM62203 (3), U01CA062502 (3), N01CM62202 (2), P30CA014520 (2), P30CA014599 (2), P30CA069533 (2), P30CA072720 (2), U01CA062491 (2), U10CA027469 (2), U10CA180820 (2)